TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) clinical trials
Formerly part of BridgeBio, Apr 30, 2024 · source ↗
The registry lists 3 studies whose lead sponsor is TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics). 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 1, 2026.
Before and after it left BridgeBio
- First submitted before TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) left BridgeBio
- 1
- First submitted after TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) left BridgeBio
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)3 studies
Something wrong with this grouping? Tell us on the BridgeBio page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All BridgeBio studies →
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsRecruitingNCT06625775Phase 1
Sponsor listed in the registry: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · First submitted after TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) left BridgeBio
- Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerRecruitingNCT06343402Phase 1
Sponsor listed in the registry: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · First submitted before TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) left BridgeBio
- BBO-11818 in Adult Subjects With KRAS Mutant CancerRecruitingNCT06917079Phase 1
Sponsor listed in the registry: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · First submitted after TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) left BridgeBio